Live data · NADAC + Part D CY24 · reviewed daily

Liraglutide (Saxenda)

GLP-1 Receptor Agonist class · 6 generic manufacturers · 8 ANDAs filed at FDA.

First FDA approval2010-01-25
Generic availableYes · 6 mfrs
Shortage statusActive shortage
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$383.1M in CY2024 Part D spend457K claims · 170K beneficiaries · 329 plans surveyed

Lowest NADAC
$30.63/unit
12 NDCs benchmarked, lowest of all strengths.
Average NADAC
$46.67
Across all dosage forms in distribution.
Highest NADAC
$87.82
Range is tight.
Plans with PA
97 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Liraglutide used for?

Liraglutide is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Liraglutide?

Yes. 8 ANDAs filed at FDA, 6 generic manufacturers currently shipping.

How much does my plan pay for Liraglutide?

Across 329 Part D plans, Liraglutide averages $46.67/unit (NADAC). Lowest available: $30.63/unit. Highest in distribution: $87.82/unit.

Is Liraglutide on the FDA shortage list?

Yes. Liraglutide is currently listed as an active FDA shortage.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (12 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.